NACT non-responders’ PBMCs previously stimulated with PMA/ionomycin or by TCR engagement are capable of reducing the breast cancer cells’ viability. (A) Percentage of HLA-DR+ CTLs in PBMCs of NACT-responders (R, white bar, n = 12), NACT-responders with a canonical stimulation of PMA/ionomycin (R St, white bar, n = 10), NACT-responders with TCR stimulation (R TCR, white bar, n = 4), NACT non-responders (NR, black bar, n = 11), NACT non-responders stimulated with PMA/ionomycin (NR St, black bar, n = 12), and NACT non-responders with TCR stimulation (NR TCR, black bar, n = 6). (B) Viability of MCF-7 cells in co-culture with NACT-responders’ PBMCs (R, white bars, n = 4–11) or with NACT non-responders’ PBMCs (NR, black bars, n = 6–11) in the presence/absence of doxorubicin (Doxo), with or without previous canonical stimulation (PMA/ionomycin) and with or without previous TCR stimulation. (C) IFN-γ production of stimulated NACT-responders’ PBMCs with PMA/ionomycin (R (St), white bar, n = 11) or with TCR stimulation (R (TCR), white bar, n = 4); and stimulated NACT non-responders’ PBMCs with PMA/ionomycin (NR (St), black bar, n = 12) or with TCR stimulation (NR (TCR), black bar, n = 6) after 4 days of co-culture with MCF-7 cells. (D) Viability of MDA-MB-231 cells in co-culture with NACT-responders’ PBMCs (R, white bars, n = 4–10) or with NACT non-responders’ PBMCs (NR, black bars, n = 6–12) in the presence/absence of doxorubicin (Doxo), with or without previous canonical stimulation (PMA/ionomycin) and with or without previous TCR stimulation. (E) IFN-γ production of stimulated NACT-responders’ PBMCs with PMA/ionomycin (R (St), white bar, n = 6) or with TCR stimulation (R (TCR), white bar, n = 4); and stimulated NACT non-responders’ PBMCs with PMA/ionomycin (NR (St), black bar, n = 9) or with TCR stimulation (NR (TCR), black bar, n = 6) after 4 days of co-culture with MDA-MB-231 cells. Data are represented as mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.